Background and objective: The effect of angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism on risk or progression of immunoglobulin A nephropathy (IgAN) is still debated. Therefore, a meta-analysis was performed to evaluate the association of ACE gene polymorphism with IgAN in different ethnic groups. Method: A predefined search strategy was performed to collect data from electronic databases. Results: Twenty articles were identified for the analysis of the relationship between ACE polymorphism and IgAN risk, including 11 in Asians and nine in Caucasians. There was a markedly positive association between the D allele or DD genotype and IgAN risk in Asians (OR = 1.27, p = 0.006; OR = 1.83, p < 0.0001). However, a link between D allele or DD genotype and IgAN risk was not found in Caucasians (OR = 1.04, p = 0.46; OR = 1.13, p = 0.12). Ten investigations were included for analysis of the association of ACE polymorphism with IgAN progression, including six in Asians and four in Caucasians. These data did not support a link between the ACE D allele or DD genotype and IgAN progression in Asians and Caucasians (Asians: D: OR = 1.03, p = 0.80; DD: OR = 1.43, p = 0.16; Caucasians: D: OR = 1.29, p = 0.22; DD: OR = 1.31, p = 0.17). Conclusions: The D allele or DD genotype is associated with IgAN risk in Asian, but not in Caucasian populations; there was no significant association between the D allele or DD gene and IgAN progression for Asians and Caucasians.
Introduction
Immunoglobulin A nephropathy (IgAN) is one of the most common varieties of primary glomerulonephritis and is characterised by predominant immunoglobulin A deposition in the mesangium. 1 It was initially regarded as a disease with a favourable prognosis, but data from long-term follow-up studies have revealed that IgAN may progress to end-stage renal failure in up to 30% of patients with a followed-up period of 20 years. 2 The role of the reninangiotensin system (RAS) has been well documented in the susceptibility and progression of many renal diseases.
The angiotensin-converting enzyme (ACE), a key enzyme in the RAS, plays an important role in the development of hypertension and progression of renal diseases. 3 Regulation of circulation and probably tissue ACE activity are under strong genetic control. The ACE gene located on chromosome 17q23 has an insertion/deletion (I/D) polymorphism in the non-coding region of the gene. 4 Polymorphic variations of the ACE gene correlate with the levels of circulating and tissue ACE, and the DD genotype shows the highest levels. The DD genotype or D allele has been suggested as an independent risk factor for progressive glomerular disease. The DD genotype was found to be over-represented in the patient suffering from renal parenchymal damage. 5 However, findings have been controversial since the first investigation was reported. The aim of our study is to evaluate the effect of this polymorphism on the susceptibility and progression of IgAN by performing a meta-analysis using all studies published until March 2010.
Materials and methods

Identification of studies
A computerised literature search on PubMed, Cochrane Library and CBM-disc (China Biological Medicine Database) as of March 2010 was performed using the key words of angiotensin-converting enzyme polymorphism and immunoglobulin A nephropathy. References from retrieved studies were checked for any additional reports, and we only included investigations published in English and Chinese. Inclusion criteria were: (1) a case-control study; (2) an outcome of IgAN; (3) at least two comparison groups (IgAN group vs. control group); and (4) the genotype frequencies of control group consistent with Hardy-Weinberg equilibrium (HWE). For analysis of the association between ACE I/D polymorphism and IgAN risk, 20 reports were included, and 11 articles were from Asian countries. Ten investigations, including six reports for Asians, were included in our study for exploring the relationship between gene polymorphism of ACE and progression of IgAN.
Data extraction
Two authors extracted data independently and in duplicate, and reached agreement on all items, including: the first author's last name, journal and year of publication, ethnicity of the study population, genotypes and numbers of cases and controls. Frequencies of alleles were calculated for cases and controls from the corresponding genotype distribution. The results were compared and disagreements were discussed and resolved with consensus.
Statistical analysis
To test the population stratification, a chi-square test using a web-based program was applied to determine whether genotype distribution of the control population reported conformed to HWE (HWE p < 0.05 was considered significant). Available data were entered into Cochrane Review Manager (RevMan, version 4.2.8) and analysed. The pooled statistic was calculated using the fixed-effect model, but a random-effect model was conducted if the p-value of the heterogeneity test was less than 0.1. Results were expressed with odds ratios (OR) for dichotomous data and weighted mean differences (WMD) for continuous data, and 95% confidence intervals (CI) were also calculated. For the overall OR or WMD to be deemed statistically significant, a value of p < 0.05 was required. Heterogeneity between included articles was tested using the chi-square test. We classified the studies into studies in Caucasians and in Asians, because genotype frequencies and prevalence of IgAN were different among ethnic groups. When the standard error (SE) was reported in the original article, the value of the standard deviation (SD) was calculated, and all descriptive data were expressed as mean ± SD.
Results
Study characteristics
In total, 28 articles were identified for the analysis of the association between ACE I/D polymorphism and IgAN onset. Three studies 6-8 did not mention control group data and were excluded. In five articles 9-13 the genotype distributions in the controls were significantly deviated from HWE, and these were not included in our meta-analysis. Thus, 20 articles were entered into this meta-analysis; 11 were reports which had been conducted in Asian countries and nine articles described studies in Caucasians (table 1) .
Ten articles were identified for exploring the relationship between ACE I/D polymorphism and IgAN progression. Six of the included reports had been performed in Asians and four in Caucasians. The association between genetic polymorphism of ACE and urinary protein quantity for 24 h was analysed in the case group.
Association of the ACE polymorphism with IgAN risk
In total, 20 studies [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] were included in our study; the Asian studies contained 2002 IgAN patients and 2002 controls, whereas and the studies in Caucasian subjects included 2678 IgAN patients and 3674 controls. Details of the individual studies are shown in table 1. The total frequency of the D allele in the control group was 43.8% in overall populations, and a lower frequency for the D allele was observed in the control group of the Asian population compared with that in Caucasians (32.6% vs. 57.6%). The frequency of the DD genotype in the control group in Asians was significantly lower than that in Caucasians (10.1% vs. 34.0%). The IgAN risks in different studies according to the three ACE genotype groups are presented in table 2. Only five studies reported a positive effect of the ACE I/D polymorphism on IgAN susceptibility. 14, 16, 21, 26, 33 From the 20 studies, the genotype frequencies for DD, ID, and II in the control group and the IgAN group were 10.1%, 45.0% and 44.9%, and 17.0%, 41.5% and 41.5% in Asians; and 34.0%, 47.2% and 18.8%, and 33.3%, 45.2% and 21.5% in Caucasians. In our meta-analysis, there was a significantly positive association between the D allele or DD genotype and IgAN risk in Asians (figure 1, 3). However, these data did not support a link between D allele or DD genotype and IgAN onset in Caucasians (figure 2, 4). Interestingly, the II genotype seemed not play a protective role against IgAN onset in the Caucasian population (OR = 1.05, p = 0.58) but the effect was positively significant in Asians (OR = 0.81, p = 0.02). When we analysed the D allele, DD genotype and II gene for IgAN susceptibility for overall populations, the results indicated that the association was positively significant for the DD genotype or D allele (DD: OR = 1.28, p = 0.0003; D allele: OR = 1.14, p = 0.002), but the II allele seemed not play a positive role against IgAN onset (OR = 0.92, p = 0.20).
Association of the ACE polymorphism with IgAN progression
Some 25 case-control design studies concerning the association of the ACE I/D polymorphism with IgAN progression were initially identified. Only those reports with a mean follow-up time of >1 year were included in this meta-analysis. We found three studies 3,20,34 which were performed by univariate/multivariate regression analysis, one investigation 12 which did not report follow-up time, and four reports 6, 21, 25, 27 which did not show detailed data. Five reports 7, 16, 22, 35, 36 where the IgAN patients were treated with ACE inhibitor (ACEi) were excluded. One investigation 29 included an African-American population for analysis, and we did not include it in our study for the analysis for Caucasians. Two articles 32, 37 included data from the same patients, thus we excluded one 37 from our analysis. Consequently, 10 studies 8, 15, 28, 30, 32, [38] [39] [40] [41] [42] were included in our meta-analysis. The Asian studies contained 225 progression and 450 non-progression patients, whereas Caucasian studies included 213 progression and 348 non-progression patients, with a follow-up time ranging from 1-15 years. The results of the meta-analysis of the association between ACE polymorphism and IgAN progression are detailed in table 3. The gene frequencies for DD, ID, and II for non-progression of IgAN and progression of IgAN were 11.8%, 44.2% and 44.0%, and 14.2%, 40.0% and 45.8%, respectively, in Asians; and 34.5%, 44.5% and 20.0%, and 40.4%, 43.2% and 16.4%, respectively, in Caucasians. The frequency of the DD genotype in Asians in the non-progression group and progression group was significant lower than in Caucasians (11.8% vs. 34.5%, 14.2% vs. 40.4%). When we calculated the association of the D allele and DD genotype with IgAN progression in Asians, Caucasians and overall populations, the results showed that the association was not positively significant. Interestingly, the II genotype seemed not play a protective role against IgAN progression for Asians, Caucasians and overall populations. The results are detailed in table 3.
Relationship between the ACE polymorphism and 24-h urine protein excretion
For the analysis of 24-h urine protein excretion in patients with IgAN, an association of ACE polymorphism was observed (DD vs. II: WMD = 0.25 (0.15, 0.34), p < 0.00001) ( figure 5 ). However, there were only four investigations 16, 23, 33, 40 included in our analysis, all of which were performed in Asians. One report 14 performed in Caucasians did not mention the SD value of 24-h urine protein excretion for our analysis, thus we excluded it in our metaanalysis. However, this study reported that genotype distributions of ACE (DD vs. II) were not different for 24-h urine protein excretion in IgAN patients in Caucasians.
Discussion
The results of this meta-analysis showed the effects of population origin. Asian populations showed significance under the different alleles, whereas studies in Caucasians produced non-significant results. A lower frequency of the DD homozygote was found in the normal Asian population when compared with Caucasians. True race-specific genetic effects could explain this pattern of results, since functional analyses of variation in the ACE gene have indicated that different loci control ACE levels in particular racial groups. 43 The need for cumulative and recursive cumulative meta-analysis has already been highlighted. The stability in the relative change in OR indicated that there was enough evidence to draw a safe conclusion about the modifying effect of ACE I/D polymorphism in the risk and progression of IgAN in Asians but not for Caucasians. We found some errors in a previous meta-analysis; 44 for example, the genotype frequencies in the control group of Chen et al. 12 were not consistent with HWE, although it was regarded as equilibrium. Our analysis, including some reports published in Chinese, was performed to explore the relation between ACE subtypes and risk or progression of IgAN. We have perhaps demonstrated a more reliable result compared with previous studies, especially for Asians. For the analysis of association between the risk of IgAN and the ACE gene polymorphism, the genotype frequencies were not consistent with HWE in some studies, which were excluded from our meta-analysis. There were only five studies 14, 16, 21, 26, 33 reporting a positive effect of the ACE I/D polymorphism on IgAN, four from Asian countries and one in Caucasians. We pooled the data from available published investigations to compute an estimate of the association between I/D polymorphism of ACE gene locus and IgAN risk. We calculated the ORs for the D allele, DD gene and II genotype, and the results indicated that there were some differences between Asians and Caucasians. We found that the D allele and DD genotype were associated with risk of IgAN in Asians and for overall populations, but not for Caucasian populations. We also discovered the effect of the II genotype was positively significant in Asians, but not in Caucasians or in subjects overall. The D allele and DD variant genotype may be associated with an increased risk of IgAN in Asian populations, but not in Caucasians. The frequency of the ACE DD gene in the control group for Caucasians was much higher than that in Asians, but the DD genotype had no increased risk of IgAN in Caucasians, suggesting a possible role of continental differences in genetic backgrounds and environment. Our result was similar to the report by Yong and colleagues. 44 However, Yong et al., including only five reports for analysis, found that the D allele was not associated with an elevated IgAN risk in Asians. Our investigation indicated that carrying the D allele conferred significant risk to IgAN susceptibility. Furthermore, Schena et al. 27 reported that the ACE I/D gene polymorphism did not contribute to the genetic susceptibility of the development of IgAN in Asians or Caucasians, but their meta-analysis included only three studies in Asians and four investigations in Caucasians. We consider our conclusion to be more reliable, for the reason that our analysis was based on a substantially larger number of studies, including 11 studies in Asians and nine reports in Caucasian populations.
Opinion regarding the association of the ACE I/D gene polymorphism with IgAN progression has been inconsistent in recent years. Ten studies in this meta-analysis were performed to indicate whether the ACE gene polymorphism may be involved in the progression of IgAN. Studies conducted in past decades have demonstrated variable therapeutic efficacy of ACEi on the progression of IgAN, 7, 16, 22, 35, 36 and that ACEi can reduce the serum level of ACE and significantly attenuate the progressive process of IgAN. 16 As ACEi may affect the results of our analysis of the association of ACE gene polymorphism with IgAN progression, we excluded those studies from our meta-analysis. In the included studies, there were only three investigations 8, 29, 38 which reported that ACE gene polymorphism was associated with IgAN progression, one study in Asians and two in Caucasians. We conducted the analyses for the D allele, DD or II homozygote by ethnicity and overall. We found that ACE I/D gene polymorphism did not influence the progression of IgAN in Asians, Caucasians and people overall. When we used the fixed-effect model for the analysis of association between the D allele or II gene and IgAN progression for Caucasians, the p-values for the heterogeneity test were 0.09 and 0.07, and no association or a marginally significant association was observed between the D allele or II gene and increased progression of IgAN (p = 0.07 and 0.13, respectively). Consequently, a random-effect model was conducted for analysis of the association of the D allele or II gene with IgAN progression in Caucasians; we also found there was no significant association between D allele or II gene and IgAN progression (p = 0.22 and 0.39, respectively). The results of our investigation were credible. In conclusion, our meta-analysis suggested that the D allele or DD gene was not associated with IgAN progression in Asians and Caucasians. We also did not observe a marginally significant association between the II genotype and reduced risk of IgAN progression for Asians and in Caucasians. Our results were in agreement with those of Schena et al., 27 that the ACE I/D gene polymorphism does not contribute to the genetic susceptibility of the development of IgAN in Asians and in Caucasians. Our results were not consistent with Yong et al. 44 for the analysis for Asians and Caucasians, but their meta-analysis did not exclude the investigations which included patients treated with ACEi, thus the result in their study might be not reliable. Our meta-analysis included a substantially larger number of studies than the two meta-analyses mentioned above; thus, this investigation might provide a much more reliable result.
In our study, we found that the D allele or DD genotype is less common in Asians compared with Caucasians (D: 32.6% vs. 57.6%; DD: 10.1% vs. 34.0%). We also calculate the pooled OR for the association between the D allele or DD gene and IgAN susceptibility or IgAN progression for overall populations. However, it was difficult to draw a definite conclusion.
The occurrence of proteinuria is related to change of glomerular filtration membrane integrity. In this metaanalysis, we investigated the relation between ACE gene polymorphism and 24-h urine protein excretion in IgAN patients. A notable association was observed between the effect of DD/II genotype and 24-h urine protein excretion (DD vs. II: WMD = 0.25 (0.15, 0.34), p < 0.00001) in Asians. The number of included articles was small, and it was difficult to draw a confident conclusion. However, to a certain extent, DD may be a risk factor for increased 24-hour urine protein excretion in Asians.
In this study we included four articles 13, 19, 24, 33 published in Chinese, and it was difficult to search for and obtain the full text of studies in some other countries. Therefore, these reports could be classified as grey literature. We conducted an analysis of non-grey literature (published in English) and found the results were similar to the entire pool of studies.
To a certain extent, the results in our study were reliable. We speculated that the ACE I/D gene polymorphism might affect more sensitively IgAN susceptibility in Asians than in Caucasians. These findings should be regarded cautiously because many other ingredients, such as proteinuria, were closely related to the progression of IgAN and were not excluded from all investigations. Furthermore, whether the I/D polymorphism is linked with other discrete loci involved in the IgAN prognosis is not clear.
Limitations
Some limitations should be discussed in this meta-analysis. First, heterogeneities may be present, influencing the results of our meta-analysis, although a random-effects model has been conducted. Second, a key problem in any literaturebased review and meta-analysis is that of reporting bias (we only included published literature in English and Chinese). Third, the sample sizes in some investigations are relatively small. Last but not least, a more precise estimate could be performed if more detailed individual data are available, such as creatinine clearance rate, which would allow for an adjusted analysis. Undoubtedly, the limitations mentioned above will affect our final conclusions.
Conclusions
For Asians, the results in our meta-analysis suggest that the D allele and DD variant genotype may be associated with an increased risk of IgAN. However, the D allele or DD gene may be not closely related to an elevated risk of IgAN in Caucasians. Furthermore, a marginally significant association between the D allele or DD genotype and reduced risk of IgAN progression for Asians and in Caucasians was not observed. Due to the limitations of such a metaanalysis, larger association studies or multi-centric casecontrol studies, and studies assessing gene-environment interactions are warranted to confirm these findings. Future studies, and more case-control association studies on larger, stratified populations, will also need to improve their methodological quality and the reporting of their findings, in order to increase the credibility of the evidence accumulating over time.
